Update: The status of clinical trials with kinase inhibitors in thyroid cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 5, 2014, Pages 1543-1555

  Wells Jr , Samuel A ^a   Santoro, Massimo ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AXITINIB; BORTEZOMIB; CABOZANTINIB; CHIR 265; DACTOLISIB; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; IMATINIB; MOTESANIB; NSC 737754; PACLITAXEL; PAZOPANIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHOTRANSFERASE INHIBITOR; PLACEBO; PLATINUM COMPLEX; RADIOACTIVE IODINE; RAPAMYCIN; RETINOIC ACID; SELUMETINIB; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VEMURAFENIB;

ANAPLASTIC THYROID CANCER; ARTICLE; CELL HETEROGENEITY; CHROMOSOME REARRANGEMENT; CHRONIC MYELOID LEUKEMIA; DIFFERENTIATED THYROID CANCER; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESISTANCE; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; EXTERNAL BEAM RADIOTHERAPY; GENE MUTATION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PERSONALIZED MEDICINE; POORLY DIFFERENTIATED THYROID CANCER; PRIORITY JOURNAL; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS AS TOPIC; HUMANS; PROTEIN KINASE INHIBITORS; THYROID NEOPLASMS;

EID: 84899957735     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2622     Document Type: Article

References (141)

1. American Cancer Society. Cancer Facts and Figures 2012. Atlanta, GA: American Cancer Society; 2012.
2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164-2167.
3. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009; 115:3801-3807.
4. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev. 2009;18:784-791.
5. Jung CK, Little MP, Lubin JH, et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations [published online December 20, 2013]. J Clin Endocrinol Metab. doi:10.1210/jc.2013-2503.
6. Liska J, Altanerova V, Galbavy S, Stvrtina S, Brtko J. Thyroid tumors: histological classification and genetic factors involved in the development of thyroid cancer. Endocr Regul. 2005;39:73-83.
7. Robbins J, Merino MJ, Boice JD Jr., et al. Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med. 1991;115:133-147.
8. Schlumberger MJ, Filetti S, Hay I. Nontoxic Diffuse and Nodular Goiter and Thyroid Neoplasia. 12th ed. Philadelphia, PA: Elsevier; 2011.
9. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol. 2006;13:453-464.
10. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107:2134-2142.
11. Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, WellsSAJr. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med. 2005;353:1105-1113.
12. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7:569-580.
13. Fagin JA. The Je remiah Metzger Lecture: intelligent design of cancer therapy: trials and tribulations. TransAmClin Climatol Assoc. 2007;118:253-261.
14. Lee J, Hwang JA, Lee EK. Recent progress of genome study for anaplastic thyroid cancer. Genomics Inform. 2013;11:68-75.
15. Liu X, Bishop J, Shan Y, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013;20:603-610.
16. Santoro M Melillo RM Fusco A. RET/PTC activation in papillary thyroid carcinoma European Journal of Endocrinology Prize Lecture. Eur J Endocrinol. 2006 155 645-653.
17. SantoroM,Thomas GA, Vecchio G, et al. Gene rearrangement and Chernobyl related thyroid cancers. Br J Cancer. 2000;82:315-322.
18. Ciampi R, Nikiforov YE. RET/ PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology. 2007;148: 936-941.
19. Ciampi R, Knauf JA, Kerler R, et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest. 2005;115:94-101.
20. Leeman-Neill RJ, Brenner AV, Little MP, et al. RET/PTC and PAX8/PPAR-chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics. Canc er. 2013;119:1792-1799.
21. Ricarte-Filho JC, Li S, Garcia-Rendueles ME, et al. Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers. J Clin Invest. 2013;123:4935-4944.
22. Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPAR-1 fusion oncogene in human thyroid carcinoma [published correction appears in Science. 2000;289(5484):1474]. Scien ce. 2000;289: 1357-1360.
23. Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR-rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicul ar carcinoma. J Clin Endocrinol Metab. 2003;88:2318-2326.
24. Nelen MR, Kremer H, Konings IB, et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype corr elations. Eur J Hum Genet. 1999;7:267-273.
25. Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009;69:4885-4893.
26. Todaro M, Iovino F, Eterno V, et al. Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res. 2010;70: 8874-8885.
27. DeLellis R, Lloyd R, Heitz P, Eng C. Pathology and Genetics of Tumors of Endocrine Organs (IARC WHO Classification of Tumors). Lyon, France: World Health Organization, IARC Press; 2004.
28. Ganly I, Ricarte Filho J, Eng S, et al. Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. J Clin Endocrinol Metab. 2013;98:E962-E972.
29. Lakhani VT, You YN, Wells SA. The multiple endocrine neoplasia syndromes. Annu Rev Med. 2007;58:253-265.
30. Moura MM, Cavaco BM, Pinto AE, Leite V. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab. 2011;96:E863-E868.
31. Ciampi R, Mian C, Fugazzola L, et al. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid. 2013;23:50-57.
32. Sherman SI. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010;22:464-468.
33. Matuszczyk A, Petersenn S, Bocki sch A, et al. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res. 2008;40:210-213.
34. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
35. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355:2733-2743.
36. Al-Lazikani B, Banerji U, Wo rkman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol. 2012;30: 679-692.
37. Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Associ-ation guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012;22:1104-1139.
38. Weinstein IB Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science. 2002 297 63-64.
39. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417.
40. Cohen EE, Ro sen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26:4708-4713.
41. Sherman SI, Wi rth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008; 359:31-42.
42. Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazop anib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010;11:962-972.
43. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26: 4714-4719.
44. Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-p ositive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16: 5260-5268.
45. Schlumberger MJ, Elise i R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009;27:3794-3801.
46. Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010;28:2323-2330.
47. De Souza JA, Busaidy N, Zimri n A, et al. Phase II trial of sunitinib in medullary thyroid cancer (MTC). J Clin Oncol. 2010;28(suppl): 5504.
48. Wells SA Jr., Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28:767-772.
49. Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95:26 64-2671.
50. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011;29:2660-26 66.
51. Wells SA Jr., Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30 : 134-141.
52. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92: 3466-3469.
53. Frank-Raue K, FabelM,Delorme S, Haberkorn U, Raue F. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol. 2007;157:215-220.
54. Pennell NA, Daniels GH, Haddad RI, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008; 18:317-323.
55. Hong DS, Cabanillas ME, Wheler J, et al. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocri nol Metab. 2011;96:997-1005.
56. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
57. Hayes DN, Lucas AS, Tanvetyanon T, et al. Phase II efficacy a nd pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. 2012;18:2056-2065.
58. Kloos RT, Ring el MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27:1675-1684.
59. Leboulleux S Bastholt L Krause T et al. Vandetanib in locall y advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial Lancet Oncol. 2012 13 897-905.
60. HaHT, Lee JS, Urba S, et al.Aphase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid. 2010;20:975-980.
61. Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW, Kapiteijn E. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol. 2012;167:643-650.
62. Bible KC, Suman VJ, Menefee ME, et al.Amultiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab. 2012;97:3179-3184.
63. Savvides P, Nagaiah G, Lavertu P, et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid. 2013;23:600-604.
64. Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31:3639-3646.
65. Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.NEngl J Med. 2013; 368:623-632.
66. BroseMS,Nutting C, Jarzarb B, et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differ entiated thyroid cancer: The phase III DECISION trial. J Clin Oncol. 2013;31(suppl):4.
67. FDA Approves Nexavar to Treat Type of Thyroid Cancer. Silver Spring, MD: US Dept of Health and Human Services; November 22, 2013.
68. Engelman JA, Chen L, Tan X, et al. Effective use of PI3K andMEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008;14:1351-1356.
69. García-Rost án G, Costa AM, Pereira-Castro I, et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 2005; 65:10199-10207.
70. Liu Z, Hou P, Ji M, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab. 2008;93: 3106-3116.
71. Miller KA, Yeager N, Baker K, Liao XH, Refetoff S, Di Cristofano A. Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res. 2009;69: 3689-3694.
72. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab. 2008;93:278-284.
73. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differen tiated and anaplastic thyroid cancer. J Clin Endocrinol Metab. 2009;94:4107-4112.
74. Liu D, Xing J, Trink B, Xing M. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK i nhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer. 2010;127:2965-2973.
75. Liu R, Liu D, Xing M. The Akt inhibitor MK2206 synergizes, but perifosi ne antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. J Clin Endocrinol Metab. 2012;97:E173-E182.
76. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. Clin Cancer Res. 2011;17:6482-6489.
77. Koh YW, Shah MH, Agarwal K, et al. Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro. Endocr Relat Cancer. 2012;19:29-38.
78. Gild ML, Landa I, Ryde r M, Ghossein RA, Knauf JA, Fagin JA. TargetingmTORin RET mutant medullary and differentiated thyroid cancer cells. Endocr Relat Cancer. 2013;20:659-667.
79. Tamburrino A, Molinolo AA, S alerno P, et al. Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. Clin Cancer Res. 2012;18:3532-3540.
80. Rosove MH Peddi PF Glaspy JA. BRAF V600E inhibition in anaplastic thyroid cancer N Engl J Med. 2013 368 684-685.
81. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascu lar targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002;62:3408-3416.
82. Gramza AW, Balasubramaniam S, Fojo AT, Ward J, Wells SA. Phase I/II trial of crolibulin and cisplatin in solid tumors with a focus on anaplastic thyroid cancer: phase I results. J Clin Oncol. 2013;31:6074.
83. Mooney CJ, Nagaiah G, Fu P, et al.Aphase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid. 2009;19:233-240.
84. Sosa JA , Elisei R, Jarzab B, et al. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma [published online September 10, 2013]. Thyroid. doi:10.1089/thy.2013. 0078 .
85. Lin SF, Huang YY, Lin JD, Chou TC, Hsueh C, Wong RJ. Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy. PLoS One. 2012;7:e46726.
86. Ki m E, Matsuse M, Saenko V, et al. Imatinib enhances docetaxelinduced apoptosis through inhibition of nuclear factor-B activation in anaplastic thyroid carcinoma cells. Thyroid. 2012;22:717-724.
87. Copland JA, Marlow LA, Kurakata S, et al. Novel high-affinity PPAR-agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene. 2006;25:230 4-2317.
88. Greenberg VL, Williams JM, Cogswell JP, MendenhallM,Zimmer SG. Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells. Thyroid. 2001 ;11:315-325.
89. Koh CS, Ku JL, Park SY, et al. Establishment and characterization of cell lines from three human thyroid carcinomas: responses to all-trans-retinoic acid and mutations in the BRAF gene. Mol Cell Endocrinol. 2007;264:118-127.
90. Mitsiades CS, McMillin D, Kotoula V, et al. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab. 2006; 91:4013-4021.
91. Wunderlich A, Roth S, Ramaswamy A, et al. Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer. Endocrine. 2012;42:637-646.
92. Isham CR, Bossou AR, Negron V, et al. Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer. Sci Transl Med. 2013;5:166ra3.
93. Arlot-Bonnemains Y, B aldini E, Martin B, et al. Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines. Endocr Relat Cancer. 2008;15:559-568.
94. Sorrentino R, Libertini S, Pallante PL, et al. Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab. 2005;90:928-935.
95. Wunderlich A, Fischer M, Schlosshauer T, et al. Evaluation of aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer. Cancer Sci. 2011;102:762-768.
96. A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for The Treatment of Anaplastic Thyroid Cancer. ClinicalTrialsgov 2013:NCT01236547.
97. Marlow LA, Reynolds LA, Cleland AS, et al. Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth. Cancer Res. 2009;69:1536-1544.
98. Smallridge RC, Copland JA, Brose MS, et al. Efatutazone, an oral PPAR-agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. J Clin Endocrinol Metab. 2013;98:2392-2400.
99. Harris PJ, Bible KC. Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches. Expert Opin Investig Drugs. 2011;20:1357-1375.
100. Lerch C, Richter B. Pharmacotherapy options for advanced thyroid cancer: a systematic review. Drugs. 2012;72:67-85.
101. Haugen BR, Sherman SI. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev. 2013;34: 439-455.
102. Bernards R. A missing link in genotype-directed cancer therapy Cell. 2012 151 465-468
103. Fag in JA, TuttleRM,PfisterDG.Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2621-2624.
104. Stein B, Smith BD. Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib. Clin Ther. 2010;32:804-820.
105. Carlomagno F, Guida T, Anaganti S, et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene. 2004;23: 6056-6063.
106. Diaz LA Jr., Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486:537-540.
107. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532-536.
108. Ohashi K, Sequist LV, Arcila ME, et al. Lung can cers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci USA. 2012;109:E2127-E2133.
109. Pao W, Wang TY, Riel y GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2:e17.
110. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.NEngl J Med. 2008;359:1757-1765.
111. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363:809-819.
112. Hey F, Pritchard C. A new mode of RAF autoregulation: a further complication in the inhibitor paradox. Cancer Cell. 2013;23:561-563.
113. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973-977.
114. Villanueva J, Vu ltur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18:683-695.
115. Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resis-tance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29:3085-3096.
116. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468:968-972.
117. Poulikakos PI, P ersaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480:387-390.
118. Solit DB, Jänne PA. Translational medicine: primed for resistance. Nature. 2012;483:44-45.
119. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483:100-103.
120. Montero-Conde C, Ruiz-Llorente S, Dominguez JM, et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors att enuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 2013;3:520-533.
121. Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitor s in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2011;17:1616-1622.
122. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-422.
123. Amsberg GK Koschmieder S. Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia Onco Targets Ther. 2013 6 99-106.
124. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367:2075-2088.
125. Zhu GR, Ji O, Ji JM, et al. Combining nilotinib and imatinib improves the outcome of imatinib-resistant blast phase CML. Acta Haematol. 2012;127:152-155.
126. Gó mez-Almaguer D, Tarín-Arzaga L, Cantú- Rodríguez O, Ceballos-Ló pez A. More about imatinib and nilotinib combination therapy in chronic myeloid leukemia. Acta Haematol. 2013;129: 18-19.
127. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883-892.
128. Aparicio S , Caldas C. The implications of clonal genome evolution for cancer medicine. N Engl J Med. 2013;368:842-851.
129. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer Nat Rev Cancer. 2012;12:323-334.
130. Maley CC, Galipeau PC, Finley JC, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet. 2006;38:468-473.
131. Gandolfi G, Sancisi V, Torricelli F, et al. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumo r progression. J Clin Endocrinol Metab. 2013;98:E934-E042.
132. Guerra A, Sapio MR, Marotta V, et al. The primary occurrence of BRAF(V600E)is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012;97:517-524.
133. GhosseinRA,Katabi N, Fagin JA. Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression. J Clin Endocrinol Metab. 2013;98:E1 414-E1421.
134. Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab. 2013; 98:E1852-E1860.
135. Knauf JA, Ma X, Smith EP, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Re s. 2005; 65:4238-4245.
136. Chakravarty D, Santos E, Ryder M, et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest. 2011;121: 4700-4711.
137. Zhu Z, Ciampi R, Nikiforova MN, Gandhi M, Nikiforov YE. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection metho ds and genetic heterogeneity. J Clin Endocrinol Metab. 2006;91:3603-3610.
138. Von Hoff DD, Stephenson JJ Jr., Rosen P, et al. Pilot study using molecular profiling of patients'tumors to find pot ential targets and select treatments for their refractory cancers. J Clin Oncol. 2010; 28:4877-4883.
139. Roychowdhury S, Iyer MK, Robinson DR, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med. 2011;3:111ra121.
140. Brough R, Frankum JR, Costa-Cabral S, Lord CJ, Ashworth A. Searching for synthetic lethality in cancer. Curr Opin Genet Dev. 2011;21:34-41.
141. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.